Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Stiefel Adds Psoriasis/Atopical Dermatitis Candidate In Licensing Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

For about $34 million, Stiefel gets development and commercialization rights in most of the world to a novel, non-steroidal, topical anti-inflammatory compound in Phase II.

You may also be interested in...



Deals Of The Week: Stiefel/Welichem, Bayer/Covance, Ensemble/Genentech

Activist investor Carl Icahn is at it again, announcing plans May 30 to propose a minority slate of new board members for patent-cliff-challenged specialty pharma Forest Laboratories.

GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal

Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.

Stiefel Labs Adds Connetics’ Topical Delivery Technology With Acquisition Of Dermatology Firm

Completion of the $640 million acquisition combines Stiefel’s dermatology portfolio with Connectics’ patented drug delivery technology.

Topics

Related Companies

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel